Unprofitable Tech and Bio Names Show Mixed Fundamentals

Three publicly traded companies listed on NASDAQ are currently operating with negative GAAP margins, creating a distinct split in their fundamental trajectories. According to data reviewed by GN stocks/nasdaq, Myriad Genetics, Asure Software, and Blink Charging each face the challenge of converting operational losses into sustainable profitability. The divergence lies in their revenue trends and capital efficiency, with one showing clear signs of stagnation while the others exhibit growth indicators that may justify further scrutiny.

Myriad Genetics reported a trailing 12-month GAAP operating margin of -12.2%, reflecting a period of flat sales over the last two years. The company, which develops genetic tests for oncology and women’s health, has seen its earnings per share decline by 7.4% annually over the past five years, a trend exacerbated by new share issuances. With a stock price of $3.77, the firm trades at 0.4x forward price-to-sales, a valuation that may reflect market skepticism about its ability to secure high-cost debt or generate organic growth without dilutive fundraising.

Asure Software Shows Billings Momentum

Asure Software operates in a niche market providing human capital management to small and medium-sized businesses, achieving a trailing 12-month GAAP operating margin of -1.2%. Unlike its peers, the company has maintained a 16.1% annual sales growth rate over the last two years, driven by a product suite that integrates seamlessly into existing business workflows.

The company’s billings have grown by an average of 26.2% over the past year, indicating a strong pipeline of new contracts that may expand in value over time. This growth in contracted revenue suggests that Asure is successfully acquiring customers in underserved metropolitan areas where HR expertise is scarce, supporting a valuation of 1.5x forward price-to-sales at its current price of $8.58.

Blink Charging Leverages Gross Margin

Blink Charging, a manufacturer and operator of electric vehicle charging networks, reported a significantly deeper loss with a trailing 12-month GAAP operating margin of -52.7%. Despite this heavy operating burn, the company maintains a gross margin of 32.5%, providing a buffer for marketing and product development expenditures.

Over the last two years, Blink Charging’s earnings per share have improved by 35.7% annually, outperforming its peers in the EV infrastructure sector. This improvement in per-share metrics, combined with its status as one of the first EV charging companies to go public, suggests a path toward operational scale. The stock currently trades at $0.54, representing a 0.8x forward price-to-sales ratio.

Valuation Metrics Reflect Risk Profiles

The valuation multiples for these three firms highlight the market’s differentiation of their risk profiles. Myriad Genetics’ 0.4x forward P/S ratio is the lowest of the group, potentially signaling a deep value trap or a significant risk of capital erosion if revenue stagnation continues. In contrast, Asure Software’s 1.5x multiple reflects a premium for its consistent billings growth and lower operating loss.

Blink Charging sits in the middle at 0.8x forward P/S, a valuation that may account for its high growth in EPS but also its substantial operating losses. For investors, the key distinction is that Asure and Blink are demonstrating growth in top-line or per-share metrics, whereas Myriad is facing a headwind from share dilution and flat sales, making its path to profitability less certain based on current data.